Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis
NCT ID: NCT01479231
Last Updated: 2012-04-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1/PHASE2
INTERVENTIONAL
2012-03-31
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)?
NCT01865825
The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors
NCT01404832
Food Antigen in Eosinophilic Esophagitis
NCT02434705
The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
NCT00728481
Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis
NCT00255151
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
dexlansoprazole
dexlansoprazole
Dexlansoprazole 60 mg daily for 6 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dexlansoprazole
Dexlansoprazole 60 mg daily for 6 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 14 eosinophils / hpf on biopsies from esophagus
* Abnormal validated Mayo dysphagia questionnaire (MDQ-30) (question 2"yes", question 4 \> "moderate" and question 7 \> "once a week")
* Clinically performed EGD with \> 14 eosinophils/hpf completed within last 3 months
Exclusion Criteria
* Dilatation of esophagus at time of index endoscopy
* Treatment with topical steroid within 3 months of index endoscopy
* Treatment with PPI in last 30 days prior to index EGD
Patient population - adults with EoE recruited from Mayo Clinic Rochester, MN patient population
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jeffrey A Alexander
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeffrey A Alexander, MD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11-003759
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.